News

AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)

February 16, 2022

AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer

January 13, 2022

AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS

January 16, 2020

AI Therapeutics Announces that a Common LAM-002 Mechanism in Cancer and Neurodegenerative Diseases Shows Antitumor Activity in the Clinic and Hope for ALS